{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:51:07Z","timestamp":1762505467213},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:00:00Z","timestamp":1234224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s00520-009-0591-9","type":"journal-article","created":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T05:04:44Z","timestamp":1234155884000},"page":"469-470","source":"Crossref","is-referenced-by-count":2,"title":["Hyperparathyroidism secondary to zoledronic acid infusion: case report"],"prefix":"10.1007","volume":"17","author":[{"given":"Meral","family":"Say\u0131n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gozde","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,10]]},"reference":[{"key":"591_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","volume":"4","author":"H Fleisch","year":"2002","unstructured":"Fleisch H (2002) Development of bisphophonates. Breast Cancer Res 4:30\u201334. doi: 10.1186\/bcr414","journal-title":"Breast Cancer Res"},{"key":"591_CR2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF02555852","volume":"49","author":"AM Flanagan","year":"1991","unstructured":"Flanagan AM, Chambers TJ (1991) Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407\u2013415. doi: 10.1007\/BF02555852","journal-title":"Calcif Tissue Int"},{"issue":"Suppl","key":"591_CR3","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(Suppl):2961\u20132978. doi: 10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","journal-title":"Cancer"},{"key":"591_CR4","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1210\/endo.141.12.7921","volume":"141","author":"JE Fisher","year":"2000","unstructured":"Fisher JE, Rodan GA, Reszka AA (2000) In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793\u20134796. doi: 10.1210\/en.141.12.4793","journal-title":"Endocrinology"},{"key":"591_CR5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342. doi: 10.1038\/nature01658","journal-title":"Nature"},{"key":"591_CR6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ (2006) Management of adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897\u2013907. doi: 10.1093\/annonc\/mdj105","journal-title":"Ann Oncol"},{"issue":"15","key":"591_CR7","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minani H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314\u20133321. doi: 10.1200\/JCO.2005.05.116","journal-title":"J Clin Oncol"},{"issue":"15","key":"591_CR8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJM200304103481521","volume":"348","author":"CJ Rosen","year":"2003","unstructured":"Rosen CJ, Brown S (2003) Severe hypocalcaemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 348(15):1503\u20131504. doi: 10.1056\/NEJM200304103481521","journal-title":"N Engl J Med"},{"issue":"4","key":"591_CR9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2169\/internalmedicine.37.396","volume":"37","author":"A Comlekci","year":"1998","unstructured":"Comlekci A, Biberoglu S, Hekimsoy Z et al (1998) Symptomatic hypocalcaemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. Intern Med 37(4):396\u2013397. doi: 10.2169\/internalmedicine.37.396","journal-title":"Intern Med"},{"issue":"2","key":"591_CR10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1385\/ENDO:14:2:159","volume":"14","author":"A Mishra","year":"2001","unstructured":"Mishra A, Wong L, Jonklaas J (2001) Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 14(2):159\u2013164. doi: 10.1385\/ENDO:14:2:159","journal-title":"Endocrine"},{"issue":"9","key":"591_CR11","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1359\/jbmr.2001.16.9.1719","volume":"16","author":"BG Stuckey","year":"2001","unstructured":"Stuckey BG, Lim EM, Kent GN et al (2001) Bisphosphonate therapy for Paget\u2019s disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, prolonged remission. J Bone Miner Res 16(9):1719\u20131723. doi: 10.1359\/jbmr.2001.16.9.1719","journal-title":"J Bone Miner Res"},{"issue":"9","key":"591_CR12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5694\/j.1326-5377.2005.tb06797.x","volume":"182","author":"HV Nguyen","year":"2005","unstructured":"Nguyen HV, Ingram KB, Beilin J (2005) Profound hypocalcaemia after zoledronic acid treatment. Med J Aust 182(9):494\u2013495","journal-title":"Med J Aust"},{"issue":"8","key":"591_CR13","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.2004.99.013","volume":"22","author":"TL Breen","year":"2004","unstructured":"Breen TL, Shane E (2004) Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol 22(8):1531\u20131532. doi: 10.1200\/JCO.2004.99.013","journal-title":"J Clin Oncol"},{"key":"591_CR14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bmj.328.7435.335","volume":"328","author":"R Peter","year":"2004","unstructured":"Peter R, Mishra V, Fraser WD (2004) Severe hypocalcemia after being given intravenous bisphosphonate. BMJ 328:335\u2013336. doi: 10.1136\/bmj.328.7435.335","journal-title":"BMJ"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0591-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0591-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0591-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:45:41Z","timestamp":1589550341000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0591-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,10]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0591-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,10]]}}}